These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 3121346

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid fragment (hPTH 1-34) therapy.
    Reeve J, Arlot M, Bernat M, Charhon S, Edouard C, Slovik D, Vismans FJ, Meunier PJ.
    Metab Bone Dis Relat Res; 1981; 3(1):23-30. PubMed ID: 7266363
    [No Abstract] [Full Text] [Related]

  • 4. Human parathyroid peptide treatment of vertebral osteoporosis.
    Reeve J, Arlot ME, Bradbeer JN, Hesp R, Mcally E, Meunier PJ, Zanelli JM.
    Osteoporos Int; 1993; 3 Suppl 1():199-203. PubMed ID: 8461559
    [Abstract] [Full Text] [Related]

  • 5. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.
    Hodsman AB, Steer BM, Fraher LJ, Drost DJ.
    Bone Miner; 1991 Jul; 14(1):67-83. PubMed ID: 1868270
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis.
    Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH.
    Bone; 2000 Aug; 27(2):311-8. PubMed ID: 10913928
    [Abstract] [Full Text] [Related]

  • 8. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.
    Plotkin H, Gundberg C, Mitnick M, Stewart AF.
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2786-91. PubMed ID: 9709948
    [Abstract] [Full Text] [Related]

  • 9. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R.
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.
    Reeve J, Davies UM, Hesp R, McNally E, Katz D.
    BMJ; 1990 Aug 11; 301(6747):314-8. PubMed ID: 2393738
    [Abstract] [Full Text] [Related]

  • 15. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.
    Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT.
    Br Med J; 1980 Jun 07; 280(6228):1340-4. PubMed ID: 6992932
    [Abstract] [Full Text] [Related]

  • 16. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone.
    Liu CC, Kalu DN, Salerno E, Echon R, Hollis BW, Ray M.
    J Bone Miner Res; 1991 Oct 07; 6(10):1071-80. PubMed ID: 1796755
    [Abstract] [Full Text] [Related]

  • 17. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM.
    J Clin Invest; 1993 Mar 07; 91(3):1138-48. PubMed ID: 8450043
    [Abstract] [Full Text] [Related]

  • 18. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds.
    Podbesek R, Edouard C, Meunier PJ, Parsons JA, Reeve J, Stevenson RW, Zanelli JM.
    Endocrinology; 1983 Mar 07; 112(3):1000-6. PubMed ID: 6822201
    [Abstract] [Full Text] [Related]

  • 19. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
    Boyce RW, Paddock CL, Franks AF, Jankowsky ML, Eriksen EF.
    J Bone Miner Res; 1996 May 07; 11(5):600-13. PubMed ID: 9157775
    [Abstract] [Full Text] [Related]

  • 20. [Morphologic study of iliac crest spongiosa in patients with osteoporosis treated according to the ADFR (activation, depression of resorption, formation, repeat the cycle) with parathyroid hormone and diphosphonates (Hannover PTH I study)].
    Delling G, Dreyer T, Hahn M, Vogel M, Rittinghaus EF, Hesch RD.
    Z Orthop Ihre Grenzgeb; 1990 May 07; 128(1):1-5. PubMed ID: 2138378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.